ii. pathobiology of pulmonary arterial hypertension...pathobiology of pulmonary arterial...
TRANSCRIPT
![Page 1: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/1.jpg)
Rubin M. Tuder, M. D.
Program in Translational Lung Research
Division of Pulmonary Sciences and Critical Care
Medicine, Department of Medicine
University of Colorado, School of Medicine
PVRI
II. Pathobiology of pulmonary arterial
hypertension
European Cardiology Society, Nice, 2012
Pulmonary Hypertension: Future expectations
![Page 2: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/2.jpg)
17β estradiol CYP1B1
(Revisited) Key features of cancer
Hanaham and Weinberg, Cell 2010
HIF
Chr 13
![Page 3: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/3.jpg)
Variability of pulmonary vascular lesions
Stacher et al.,
AJRCCM, 2012
![Page 4: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/4.jpg)
Where do pulmonary vascular lesions occur?
•Number of pulmonary
Arteries (17 orders)
10^8
Elastic (orders 17-10):
3,000
Muscular (orders 9-5):
800,000
Precapillary (orders 4-1;
25 um):
70 million
![Page 5: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/5.jpg)
Predominance of PAH in women
Stacher et al., AJRCCM, 2012
Females
Males
Females
Males
Females
Males
![Page 6: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/6.jpg)
17β estradiol CYP1B1
BMPRII
HPAHSMC IPAH Sert
Overexpressor
Dehydro
epiandrosterone
Overexpression
in cancers
4 and 16-hydroxylation
of estrogen
White, MacLean. Circulation, 2012
![Page 7: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/7.jpg)
CYP1B1 causes pulmonary hypertension
2,3,4,5-tetramethoxystilbene (TMS)
CYP1B1
White, MacLean. Circulation, 2012
16-OH estrogen
![Page 8: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/8.jpg)
Morphometric parameters: control vs. PAH
Stacher et al., AJRCCM, 2012
![Page 9: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/9.jpg)
Conceptual framework for severe PAH:
selection of apoptosis resistance
Normal EC
Trigger
agent
Shear Stress Viral factors Drugs
EC death
(?apoptosis)
Tuder et al. Eur Resp J, 2001
Clonal
Growth
Neoplastic-like
![Page 10: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/10.jpg)
Hanaham and Weinberg,
Cell 2010
Key features of cancer
TGF-b (BMPR2)
12
As
![Page 11: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/11.jpg)
(Revisited) Key features of cancer
Hanaham and Weinberg, Cell 2010
HIF
Chr 13
![Page 12: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/12.jpg)
HIFs and Pulmonary Hypertension
Hypoxic
HIF-1β
GLUT
1 & 3
G
G
G
G
G-6-P
HKII
CA IX
CO₂
HCO
3-
H+
HIF-1α
![Page 13: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/13.jpg)
PH Endothelial Cells:
Shift to a Glycolytic Pathway
Xu W et al. PNAS 2006
PH ECs have less mitochondria
Normal PAH PAH +NO
Cleveland Clinic: Serpil Erzurum, Weiling Xu, Suzy Comhair,
Raed Dweik, Kewal Asosingh
![Page 14: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/14.jpg)
IPAH-ECs energetic switch:
Decreased mitochondria
Fijalkowska, Xu, et al. Am J Pathol, 2010
![Page 15: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/15.jpg)
BMPRII: worse pulmonary vascular remodeling
Stacher et al., AJRCCM, 2012
![Page 16: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/16.jpg)
Plexiform lesions
Stacher et al., AJRCCM, 2012
![Page 17: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/17.jpg)
Morphometric parameters and pathological PAH
subphenotypes: plx lesions
Stacher et al., AJRCCM, 2012
![Page 18: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/18.jpg)
Role of EC APOPTOSIS in the genesis of severe PH
SU5416+CH and MCT Models
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Con D14 D21 D30
p<0.001
p<0.001
% c
aspas
e posi
tive/
per
imet
er
Monocrotaline
Zaiman A et al. AJRCCM, 2008
0
1
2
3
4
5
6
D7 D14 D21 D42
Ac
tiv
e C
as
pa
se
3/V
es
se
l
CH
CH+SU5416
Stewart et al. Faseb Journal, 2001
CH+ SU5416Chronic hypoxia
![Page 19: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/19.jpg)
Duncan Stewart
0
10
20
30
40
50
60
70
80
90
100P < 0.0003 P < 00005
RS
VP
mm
Hg
Control MCT MCT
+Z-Asp
0
10
20
30
40
50
CH CH+SU5416 Z-Asp+CH+SU5416
Chronic Hypoxia
SU5416
Z-Asp -CH 2
PA
P (
mm
Hg
)
N=12
N=14
N=5
Control
0
10
20
30
40
50
CH CH+SU5416 Z-Asp+CH+SU5416
Chronic Hypoxia
SU5416
Z-Asp -CH 2
PA
P (
mm
Hg
)
N=12
N=14
N=5
Control
Stewart L. Faseb Journal 2001
SU5416+CHMonocrotaline
Role of EC APOPTOSIS in the genesis of severe PH
SU5416+CH and MCT Models
![Page 20: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/20.jpg)
VEGF receptor blockade: SU5416+CH rat model of human PAH
with endothelial cell proliferation
Abe et al Circulation, 2010; courtesy: Ivan McMurtry
Human IPAH
Rat IPAH-like
![Page 21: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/21.jpg)
Impact of perivascular inflammation
Stacher et al.,
AJRCCM,
2012
![Page 22: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/22.jpg)
Schistosomiasis
Egg
Cercariae
S mansoni and S japonicum
![Page 23: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/23.jpg)
US CDC
200 million people affected by Schistosomiasis
![Page 24: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/24.jpg)
Schistosomiasis-PAH
Butrous et al. Circulation, 2008; courtesy of Dr. Angela Bandeira
![Page 25: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/25.jpg)
Courtesy Prof. Zilton Andrade
FACTOR-8
Schistosomiasis-PAH: Pathology
![Page 26: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/26.jpg)
Purified ova
Cercariae
Infected mouse
Worms
Mouse model of Schisto-PH
3 weeks
![Page 27: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/27.jpg)
Th2 Peri-Egg Granulomas
Myocyte/Myofibrocyte Macrophage Eosinophil Proliferation
![Page 28: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/28.jpg)
15
20
25
30
35
-3 -2 -1 0 1 2 3 4 5 6 7
RV
SP
(m
mH
g)
Time (minutes; 0=fasudil administration)
Effect of Acute Fasudil Treatment
Unexposed
IP/IV Exposed
Schisto-PH: combined remodeling and
vasoconstriction (Rho kinase)
![Page 29: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/29.jpg)
TGF-β RIISmad3
Smad2
+/-
Lack of role for selective loss of either
Smad2 or Smad 3 in hypoxic PH
Hypoxia:
50% 3 weeks
![Page 30: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/30.jpg)
17β estradiol CYP1B1
(Revisited) Key features of cancer
Hanaham and Weinberg, Cell 2010
HIF
Chr 13
![Page 31: II. Pathobiology of pulmonary arterial hypertension...Pathobiology of pulmonary arterial hypertension European Cardiology Society, Nice, 2012 Pulmonary Hypertension: Future expectations](https://reader031.vdocuments.net/reader031/viewer/2022013023/5ff6d2dd4b0701550a5da813/html5/thumbnails/31.jpg)
Acknowledgments
Univ. Colorado: Elvira Stacher (Univ. of Graz), Brian Graham,
James Hunt, Aneta Gandjeva, Carlyne Cool, Steve Groshong
University of Michigan (DTC): Valerie McLaughlin, Marsha
Jessep
Univ. Alabama: William Grizzle
PHBI: Transplant sites: Alleghene University of Medical Sciences (PI: Raymond L. Benza, M.D.);
Baylor College of Medicine (George Noon, M.D.); Cleveland Clinic (PI: Serpil Erzurum, M.D.);
Duke University (PI: Pang-Chieh Jerry Eu, M.D.); Stanford University-UCSF (PI:: Marlene
Rabinovitch, M.D.); University of Alabama (PI: Keith Wille, M.D.; prior PI: Raymond L. Benza,
M.D.); University of California, San Diego (PI: Patricia Thistlethwaite, M.D., Ph.D); Vanderbilt
University (Barbara Meyrick, Ph.D..
CMREF